ALFA FinderNSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹23.68
- Market cap
- ₹130.7 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 53.9×Sector 43.8×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Q2 FY27 Results: Net Profit ₹1.2 Cr, Up 500.0% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+44.8% YoY) and net profit of ₹1.2 Cr (+500.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.2 Cr · +500.0% YoY
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals filed its RTA report for October 2026 on re-lodgement of physical share transfers. All request counts for the month are NIL.
Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Other results update announcements
All →Niyogin Fintech Results Update
Niyogin Fintech's CEO letter reports Q2 FY27 net revenue of Rs 23.9 Cr and PBT ex-ESOP loss of Rs 4.4 Cr. Composite scheme awaits final NCLT approval.
Prakash Pipes Results Update
Prakash Pipes reported Q2 FY27 net sales of ₹259 crores, up 43%, with PAT rising 72% to ₹16 crores. Half-year net sales reached ₹501 crores.
Gaudium IVF And Women Health Results Update
Gaudium IVF reported Q2 FY27 revenue of ₹37.4 crore, up 17.9% YoY, with H1 revenue at ₹56.8 crore. Two new IVF hubs commenced operations during the quarter.
Systematix Corporate Services Results Update
Systematix's Q2 FY27 adjusted revenue rose 102% QoQ to ₹56.04 crore, with PAT of ₹13.13 crore. Year-on-year revenue was flat, while H1 PAT fell to ₹8.24 crore.
TARC Results Update
TARC reported H1 FY2027 total income of ₹352.78 crore and PAT of ₹27 crore. Q2 PAT was ₹4.05 crore, versus a loss in Q2 FY2026.
Q-Line Biotech Results Update
Q-Line Biotech's H1 FY27 revenue rose 5.83% while EBITDA grew 10.02%, but PAT fell 8.06%. The release also covers a proposed 70% stake acquisition in Heidelco.